In ovarian cancers, OPCML drives inactivation and degradation of the RTKs HER2, HER4, FGFR1, FGFR3, EPHA2, and AXL [10], and the specificity of this network is underscored by identification of a group of RTKs that are unaffected by OPCML. This evidence concerns the gene EPHA2 and ovarian carcinoma.